BE896818A - Nouvelle utilisation d'analogues des prostaglandines. - Google Patents

Nouvelle utilisation d'analogues des prostaglandines.

Info

Publication number
BE896818A
BE896818A BE0/210827A BE210827A BE896818A BE 896818 A BE896818 A BE 896818A BE 0/210827 A BE0/210827 A BE 0/210827A BE 210827 A BE210827 A BE 210827A BE 896818 A BE896818 A BE 896818A
Authority
BE
Belgium
Prior art keywords
new use
prostaglandin analogs
prostaglandin
analogs
new
Prior art date
Application number
BE0/210827A
Other languages
English (en)
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BE896818A publication Critical patent/BE896818A/fr

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE0/210827A 1982-05-25 1983-05-24 Nouvelle utilisation d'analogues des prostaglandines. BE896818A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57087230A JPS58203911A (ja) 1982-05-25 1982-05-25 プロスタグランジン類似化合物を有効成分として含有する細肪障害治療剤

Publications (1)

Publication Number Publication Date
BE896818A true BE896818A (fr) 1983-09-16

Family

ID=13909053

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/210827A BE896818A (fr) 1982-05-25 1983-05-24 Nouvelle utilisation d'analogues des prostaglandines.

Country Status (4)

Country Link
US (1) US4503068A (fr)
JP (1) JPS58203911A (fr)
BE (1) BE896818A (fr)
DE (1) DE3318571A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60116628A (ja) * 1983-11-29 1985-06-24 Teijin Ltd 7−チアプロスタグランジンe↓1類製剤用組成物
JPS60169430A (ja) * 1984-02-14 1985-09-02 Teijin Ltd プロスタグランジン類製剤用組成物
DE3448257C2 (en) * 1984-07-25 1988-08-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Cytoprotective action of prostacyclin derivatives on the kidney
JPS6191136A (ja) * 1984-10-09 1986-05-09 Teijin Ltd プロスタグランジン類製剤用組成物
JPS61289034A (ja) * 1985-06-17 1986-12-19 Teijin Ltd イソカルバサイクリン類脂肪乳剤
DE3708537A1 (de) * 1987-03-13 1988-09-22 Schering Ag 6-oxoprostaglandin-e-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
WO1990007335A1 (fr) * 1988-12-23 1990-07-12 Teijin Limited Utilisation d'isocarbacyclines pour la prevention ou le traitement de maladies d'organes
CA2030344C (fr) 1989-11-22 2000-04-18 Ryuji Ueno Traitement de troubles pulmonaires a l'aide de composes de 15-ceto-prostaglandines
CA2041417C (fr) * 1990-05-01 2002-05-21 Ryuji Ueno Traitement d'une maladie du pancreas a l'aide de composes de 15-ceto-prostaglandine
CA2150287C (fr) 1994-06-03 2004-08-10 Ryuji Ueno Agent therapeutique pour les affections hepatobiliaires
ATE433754T1 (de) * 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178367A (en) * 1977-02-21 1979-12-11 Ono Pharmaceutical Co. Ltd. Prostaglandin I2 analogues
JPS55111465A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Prostaglandin i2 analog and its preparation

Also Published As

Publication number Publication date
JPS58203911A (ja) 1983-11-28
US4503068A (en) 1985-03-05
DE3318571A1 (de) 1983-12-01

Similar Documents

Publication Publication Date Title
DE3486138D1 (de) Analogen von wachstum befreiendem faktor.
FR2539129B1 (fr) Analogues amines des prostaglandines 7-oxabicycloheptane-substitues utiles comme medicaments cardio-vasculaires
YU158087A (en) Mechanism for rerouting of multiprocessor interrupts
IT1161242B (it) Analoghi di prostaglandina 7-ossabicicloeptanidrazone
NL8100959A (nl) Carbacyclische analoga.
IT1177013B (it) Analoghi interfenilene di prostaglandina 7-ossa-biciclo eptano sostituiti
BE896274A (fr) Nouvelle utilisation d'analogues de prostaglandines
DE3363460D1 (de) Carbacyclin analogues
BE896818A (fr) Nouvelle utilisation d'analogues des prostaglandines.
FR2574794B1 (fr) Analogues de prostaglandines tetrahydrothienyl-substitues a action cardiovasculaire
IT1173442B (it) Analoghi di prostaglandina 7-ossabicicloeptano sostituito
GB8722764D0 (en) Hydroxamic acid prostaglandin analogs
FR2525215B1 (fr) Analogues de la vasopressine
IT1176632B (it) Analoghi di prostaglandine di tiocarbammati 7-ossabicicloeptano sostituiti
FR2337713A1 (fr) Analogues de prostaglandines
GB8518490D0 (en) Naphtyl analogs of mevalonolacton
IT1208493B (it) Analoghi di ossaprostaglandina 7-ossabicicloeptano sostituiti.
BE896735A (fr) Utilisation d'un derive de cholecalciferol.
IT1204769B (it) Analoghi di ossaprostaglandina 7-ossabicicloeptano sostituiti
GB8710728D0 (en) Amido-carbamoyl prostaglandin analogs
ES546687A0 (es) Un procedimiento para preparacion de nuevos analogos de mitomicina.
BE851357A (fr) Analogues des prostaglandines
IL56814A0 (en) Prostaglandin analogs
BE896943A (fr) Analogues d'hormones neurohypophysaires exercant des effets inhibiteurs
BE895884A (fr) Utilisation de derives du cholecalciferol

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: ONO PHARMACEUTICAL CO. LTD

Effective date: 19860531